I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI Have others been using in this context or seen similar? #ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI